Merck gets UK approval for lung disease drug Sotatercept
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-01-01 09:43 GMT | Update On 2025-04-25 12:07 GMT
Advertisement
Merck has received approval from the UK's Medicines and Healthcare products Regulatory Agency for its therapy, sotatercept, to treat a rare lung condition.
Sotatercept gained U.S. approval in March 2024 and is sold under the brand name Winrevair. It is also approved in European Union and 30 other markets.
As per Reuters, the MHRA's approval is based on data from a study of 323 patients with pulmonary arterial hypertension, in which Merck's therapy was more effective in improving patients' ability to exercise, compared to placebo.
The U.S. drugmaker acquired sotatercept as part of its $11.5 billion acquisition of Acceleron Pharma in 2021. It has been expanding its cardiovascular drugs portfolio as it prepares for a potential hit to sales after key patents for its top-selling cancer therapy Keytruda expire later this decade.
Read also: Merck closes exclusive global license agreement for LM-299
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.